Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)

Nicola Silvestris; Oronzo Brunetti; Alessandro Bittoni; Ivana Cataldo; Domenico Corsi; Stefano Crippa; Mirko D’onofrio; Michele Fiore; Elisa Giommoni; Michele Milella; Raffaele Pezzilli; Enrico Vasile; Michele Reni

doi:10.3390/cancers12061681

Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)

Nicola Silvestris, Oronzo Brunetti, Alessandro Bittoni, Ivana Cataldo, Domenico Corsi, Stefano Crippa, Mirko D’onofrio, Michele Fiore, Elisa Giommoni, Michele Milella, Raffaele Pezzilli, Enrico Vasile, Michele Reni

Research output: Contribution to journal › Review article › peer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

Original language	English
Article number	1681
Pages (from-to)	1-28
Number of pages	28
Journal	Cancers
Volume	12
Issue number	6
DOIs	https://doi.org/10.3390/cancers12061681
Publication status	Published - Jun 2020

Keywords

Diagnosis
Follow-up
Guidelines
Pancreatic ductal adenocarcinoma
Recommendations
Treatment

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers12061681

Fingerprint

Dive into the research topics of 'Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)'. Together they form a unique fingerprint.

Cite this

Silvestris, N., Brunetti, O., Bittoni, A., Cataldo, I., Corsi, D., Crippa, S., D’onofrio, M., Fiore, M., Giommoni, E., Milella, M., Pezzilli, R., Vasile, E., & Reni, M. (2020). Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM). Cancers, 12(6), 1-28. [1681]. https://doi.org/10.3390/cancers12061681

Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma : Evidence evaluation and recommendations by the italian association of medical oncology (AIOM). / Silvestris, Nicola ; Brunetti, Oronzo; Bittoni, Alessandro et al.

In: Cancers, Vol. 12, No. 6, 1681, 06.2020, p. 1-28.

Research output: Contribution to journal › Review article › peer-review

Silvestris, N , Brunetti, O, Bittoni, A, Cataldo, I, Corsi, D, Crippa, S, D’onofrio, M, Fiore, M, Giommoni, E, Milella, M, Pezzilli, R, Vasile, E & Reni, M 2020, 'Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)', Cancers, vol. 12, no. 6, 1681, pp. 1-28. https://doi.org/10.3390/cancers12061681

@article{3c78bcd2275b41d893f12a0953eb39ea,

title = "Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.",

keywords = "Diagnosis, Follow-up, Guidelines, Pancreatic ductal adenocarcinoma, Recommendations, Treatment",

author = "Nicola Silvestris and Oronzo Brunetti and Alessandro Bittoni and Ivana Cataldo and Domenico Corsi and Stefano Crippa and Mirko D{\textquoteright}onofrio and Michele Fiore and Elisa Giommoni and Michele Milella and Raffaele Pezzilli and Enrico Vasile and Michele Reni",

year = "2020",

month = jun,

doi = "10.3390/cancers12061681",

language = "English",

volume = "12",

pages = "1--28",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI AG",

number = "6",

}

TY - JOUR

T1 - Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma

T2 - Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)

AU - Silvestris, Nicola

AU - Brunetti, Oronzo

AU - Bittoni, Alessandro

AU - Cataldo, Ivana

AU - Corsi, Domenico

AU - Crippa, Stefano

AU - D’onofrio, Mirko

AU - Fiore, Michele

AU - Giommoni, Elisa

AU - Milella, Michele

AU - Pezzilli, Raffaele

AU - Vasile, Enrico

AU - Reni, Michele

PY - 2020/6

Y1 - 2020/6

N2 - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

AB - Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

KW - Diagnosis

KW - Follow-up

KW - Guidelines

KW - Pancreatic ductal adenocarcinoma

KW - Recommendations

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85086846677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086846677&partnerID=8YFLogxK

U2 - 10.3390/cancers12061681

DO - 10.3390/cancers12061681

M3 - Review article

AN - SCOPUS:85086846677

SN - 2072-6694

VL - 12

SP - 1

EP - 28

JO - Cancers

JF - Cancers

IS - 6

M1 - 1681

ER -

Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: Evidence evaluation and recommendations by the italian association of medical oncology (AIOM)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this